1. Home
  2. MDGL vs GNRC Comparison

MDGL vs GNRC Comparison

Compare MDGL & GNRC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MDGL
  • GNRC
  • Stock Information
  • Founded
  • MDGL 2011
  • GNRC 1959
  • Country
  • MDGL United States
  • GNRC United States
  • Employees
  • MDGL N/A
  • GNRC N/A
  • Industry
  • MDGL Biotechnology: Pharmaceutical Preparations
  • GNRC Metal Fabrications
  • Sector
  • MDGL Health Care
  • GNRC Consumer Discretionary
  • Exchange
  • MDGL Nasdaq
  • GNRC Nasdaq
  • Market Cap
  • MDGL 6.1B
  • GNRC 7.5B
  • IPO Year
  • MDGL N/A
  • GNRC 2010
  • Fundamental
  • Price
  • MDGL $298.87
  • GNRC $152.37
  • Analyst Decision
  • MDGL Strong Buy
  • GNRC Buy
  • Analyst Count
  • MDGL 9
  • GNRC 18
  • Target Price
  • MDGL $420.63
  • GNRC $170.72
  • AVG Volume (30 Days)
  • MDGL 302.3K
  • GNRC 1.0M
  • Earning Date
  • MDGL 08-06-2025
  • GNRC 07-30-2025
  • Dividend Yield
  • MDGL N/A
  • GNRC N/A
  • EPS Growth
  • MDGL N/A
  • GNRC 58.27
  • EPS
  • MDGL N/A
  • GNRC 5.74
  • Revenue
  • MDGL $317,383,000.00
  • GNRC $4,348,682,000.00
  • Revenue This Year
  • MDGL $286.17
  • GNRC $5.47
  • Revenue Next Year
  • MDGL $64.17
  • GNRC $6.75
  • P/E Ratio
  • MDGL N/A
  • GNRC $26.55
  • Revenue Growth
  • MDGL N/A
  • GNRC 8.07
  • 52 Week Low
  • MDGL $200.63
  • GNRC $99.50
  • 52 Week High
  • MDGL $377.46
  • GNRC $195.94
  • Technical
  • Relative Strength Index (RSI)
  • MDGL 56.27
  • GNRC 80.09
  • Support Level
  • MDGL $291.45
  • GNRC $140.75
  • Resistance Level
  • MDGL $311.21
  • GNRC $143.70
  • Average True Range (ATR)
  • MDGL 11.25
  • GNRC 3.64
  • MACD
  • MDGL 2.31
  • GNRC 2.05
  • Stochastic Oscillator
  • MDGL 60.86
  • GNRC 96.86

About MDGL Madrigal Pharmaceuticals Inc.

Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, and premature mortality. The company's medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor agonist designed to target key underlying causes of MASH.

About GNRC Generac Holdlings Inc.

Generac designs and manufactures power generation equipment serving residential, commercial, and industrial markets. It offers standby generators, portable generators, lighting, outdoor power equipment, and a suite of clean energy products. Sales generated in the United States account for the majority of total sales.

Share on Social Networks: